CHMP recommends EMA approval of biosimilar insulin

Europe's Committee for Medicinal Products for Human Use (CHMP) recommends that the European Medicines Agency (EMA) approve Eli Lilly (LLY) and Beohringer Ingelheim's investigational compound LY2963016, a new insulin glargine product, for the treatment of type 1 and type 2 diabetes. It is the first biosimilar insulin recommended for E.U. approval. It has the same amino acid sequence as Sanofi's Lantus (insulin glargine).

The European Commission's final decision is expected in ~2 months.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs